Navigation Links
Cystinosis in Medical News

Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of del...

2009 Science Report on Genetic Disease Released by Cystinosis Research Foundation

Researchers of the genetic disease Cystinosis report encouraging news. The Cystinosis Research Foundation has published the third edition of its Science Report, which is designed to provide updates on cystinosis research under way and includes new abstracts of the 12 cystinosis grants issued in 2...

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement

...t populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis , non-alcoholic steatohepatitis ("NASH") , Huntington's Disease ("HD") , and aldehyde dehydrogenase ("ALDH2") deficiency . Raptor's ...

Cystinosis Research Network Unveils New Communication Strategy and Website

... cystinosis Research Network, a non-profit organization fundin... Lake Forest, IL (PRWEB) January 29, 2009 -- The cystinosis Research Network, a non-profit organization aimed ...ve the organization's efficacy as the voice of the cystinosis community. President and Executive Director Ch...
Cystinosis in Medical Technology

Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

...se Cysteamine ("DR Cysteamine") for the potential treatment of nephropathic cystinosis ("cystinosis"), non-alcoholic steatohepatitis ("NASH") and Huntington's Dis... Company expects to conduct its pivotal clinical study for DR Cysteamine in cystinosis in the second half of 2009 and file an NDA in 2010. In February, 2009...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

...ration ("FDA") and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), has demonstrated potential efficacy in preclinical and clin...ategy is to leverage cysteamine's known safety profile for the treatment of cystinosis and potential efficacy in several other indications. In this case, cysteami...

Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program

... the greatest potential impact. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting plat...

Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease

...an Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare, genetic lysosomal storage ...ns to initiate a pivotal study of DR Cysteamine in cystinosis patients in 2009. About Raptor Pharmaceuticals C...e dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor...

Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)

...ration ("FDA") and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare and genetic lysosomal storage disease. Raptor is dev...ments: Raptor's ability to develop DR Cysteamine for the treatment of NASH, cystinosis and other indications; Raptor's ability to formulate and manufacture DR Cys...

Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease

...tly involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from ...
Cystinosis in Medical Definition

Pathology

... , Propionic acidemia , Methylmalonic acidemia , Isovaleric acidemia , 3-Methylcrotonyl-CoA carboxylase deficiency ) - Transport ( Cystinuria , cystinosis , Hartnup disease ) - Sulfur ( Homocystinuria , Cystathioninuria ) - Urea cycle ( Argininosuccinic aciduria , Citrullinemia , Hyperammonemia...
Cystinosis in Medical Dictionary

Cystinosis

Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of the amino acid cystine. It is a genetic disorder that typically follows an autosomal recessive inheritance pattern. Cystinosis is the... Cystinosis Foundation was founded in 1983 and is an all ...
Cystinosis in Biological News

Brain-nourishing molecule may predict schizophrenia relapse

...clear. Exercise can increase BDNF levels. Two drugs currently on the market for other medical conditions erythropoietin for anemia and cysteamine for cystinosis can as well. Dr. Pillai hopes his laboratory studies of these drugs will soon result in an adjunct therapy that can help patients avoid devastating r...
Cystinosis in Biological Technology

Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008

Cystinosis Foundation Ireland to Host Event June 27-28, 2008 NOVATO, Calif., June 23 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Ted Daley, President of Raptor's clinical division, will present at the...

Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis

NOVATO, Calif., June 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD...

Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)

...expect FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. For ...LDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bi...

Raptor Pharmaceuticals Closes $10 Million Private Placement

... approval and commercialization. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(...

Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention

...r currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and NASH. For additional information, please visit http://www.raptorpharma.com . FORWARD LOOKING STATEMENTS This document contains forward-l...

Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease

...r currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and NASH. For additional information, please visit http://www.raptorpharma.com . FORWARD LOOKING STATEMENTS This docum...

Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline

...teamine is currently approved by the FDA for the management of nephropathic cystinosis ("cystinosis"), a genetic lysosomal storage disease characterized by the po...al rights to Cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases. In addition to our ongoing clinical trial i...

Raptor Pharmaceuticals Acquires Orphan Clinical Program

...ay in a clinical trial generously supported by the cystinosis Research Foundation of Irvine, CA. The active ingr...ain the lead clinical investigator for the ongoing cystinosis trial. "Although cysteamine bitartrate has been ... "Through the generous and untiring support of the cystinosis Research Foundation over the past five years, we h...
Other Tags
(Date:9/2/2015)... ... September 02, 2015 , ... A recent survey by Consumer Reports ( ... and its negative impact on consumers. It was reported that 33% are paying an ... as much as an extra $100 compared to last year. Among the drugs that ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... content, records and case management solutions and services to both government and commercial ... Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. EDAC ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available in select spas and ... PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution of the classic PIONNIÈRE ... a lipid-replenishing marine oil for intense nourishing and moisturizing. Phytomer exclusive ingredient XMF ...
(Date:9/2/2015)... ... , ... Dr. Robert G. Schwartz , the principal of Piedmont Physical ... Russian martial art system that is also a philosophy of life that focuses on ... back to the 10th century, is a Russian Martial Art that has four key ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 article ... surgeries conducted each year on teenagers, quoting a New York City-area plastic surgeon ... plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to patients and ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
Other Contents